Your browser doesn't support javascript.
loading
Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.
Lugtenburg, Pieternella J; Zijlstra, Josee M; Doorduijn, Jeanette K; Böhmer, Lara H; Hoogendoorn, Mels; Berenschot, Henriette W; Beeker, Aart; van der Burg-de Graauw, Nicole C; Schouten, Harry C; Bilgin, Yavuz M; Kersten, Marie-Jose; Koene, Harry R; Herbers, Alexandra H E; de Jong, Daphne; Hijmering, Nathalie; Lam, King H; Chitu, Dana; Brouwer, Rolf E; van Imhoff, Gustaaf W.
Afiliación
  • Lugtenburg PJ; Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Zijlstra JM; Department of Haematology, Amsterdam University Medical Centre VUmc, Amsterdam, The Netherlands.
  • Doorduijn JK; Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Böhmer LH; Department of Haematology, Haga Teaching Hospital, The Hague, The Netherlands.
  • Hoogendoorn M; Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
  • Berenschot HW; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
  • Beeker A; Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, The Netherlands.
  • van der Burg-de Graauw NC; Department of Internal Medicine, Bravis Hospital, Roosendaal, The Netherlands.
  • Schouten HC; Department of Haematology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Bilgin YM; Department of Internal Medicine, Admiraal de Ruyter Hospital, Goes, The Netherlands.
  • Kersten MJ; Department of Haematology, Amsterdam University Medical Centre AMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Koene HR; Department of Internal Medicine, St Antonius Hospital, Nieuwegein, The Netherlands.
  • Herbers AHE; Department of Haematology and Medical Oncology, Jeroen Bosch Hospital, Den Bosch, The Netherlands.
  • de Jong D; HOVON Pathology Facility and Biobank (HOP), Department of Pathology, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
  • Hijmering N; HOVON Pathology Facility and Biobank (HOP), Department of Pathology, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
  • Lam KH; Department of Pathology, Erasmus MC, Rotterdam, The Netherlands.
  • Chitu D; HOVON Data Centre, Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Brouwer RE; Department of Haematology, Reinier de Graaf Hospital, Delft, The Netherlands.
  • van Imhoff GW; Department of Haematology, University Medical Centre Groningen, Groningen, The Netherlands.
Br J Haematol ; 187(3): 347-355, 2019 11.
Article en En | MEDLINE | ID: mdl-31290569
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B Grandes Difuso / Trasplante de Células Madre / Rituximab / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Idioma: En Revista: Br J Haematol Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B Grandes Difuso / Trasplante de Células Madre / Rituximab / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Idioma: En Revista: Br J Haematol Año: 2019 Tipo del documento: Article